ANZCTR search results

The REPURPOSE Trial aims to assess the efficacy and safety of oral efavirenz in high grade serous ovarian, fallopian tube and primary peritoneal cancer. Who is it for? You may be eligible for this study if you are an adult female with platinum resistant or potentially platinum sensitive high grade serous ovarian, fallopian tube and primary peritoneal cancer. Study details All participants will receive daily oral efavirenz (600mg) for 24 months or until disease progression by RECIST 1.1 or CA125 GCIG criteria unless the clinician believes that there is a clinical benefit to continue treatment beyond progression and there is no unacceptable toxicity resulting from the treatment. Data will be collected on clinical response and incidence of adverse events. It is hoped that findings from this study will inform researchers and clinicians of the role of efavirenz in the landscape of gynaecological cancer treatment.

This study will look at experiences of family, domestic, and sexual violence in people with multiple sclerosis and other neurological conditions. Participants will complete one-time screening, surveys, and optional interviews about their experiences and care, with this information linked to medical records and the MSBase registry. Outcomes of multiple sclerosis will be followed for three years. The study aims to understand how violence affects health and wellbeing, whether it worsens MS through other illnesses and the psychological impact of trauma, and to improve how neurology recognises and responds to violence. Lessons from MS are expected to inform responses across the wider field of neurology.

The purpose of this study is to understand clinician’s and consumers’ views regarding benchmarking in general and whether and how they would like to see it applied in the Inflammatory Bowel Disease space. The dual aims will be to publish a paper that analyses and discusses the survey’s findings/responses, and ultimately, to use this information to implement safe and effective benchmarking to improve clinical care and patient outcomes in IBD. It will involve an online survey of consumers and clinicians working in IBD.

Primary aim of this research is to evaluate the impact of an integrated supportive care model on health service utilisation and consumer experience for patients living with advanced liver disease who are estimated to be in the last two years of life, and their carers.

This study aims to evaluating the effects of aerobic and resistance exercise in “stiff” heart failure. We will utilize various methods to assess the efficacy of the exercise regime in order to validate it. We postulate this regime will have a favourable effect on the structure and the function of the heart whilst providing symptomatic benefit to the patient.

The Menopausal transition is linked with reduced physical activity and mood disturbances. Microbiome-targeted therapies such as oral Lactobacillus may influence motivation and exercise via the gut-brain axis.

The aim of the NODULE study is to assess the safety, efficacy and feasibility of the Prana System for the sampling of small pulmonary (lung) nodules that are suspected of being cancerous. Who is it for? You may be eligible for this study if you are aged between 40 and 75 years and you have a lung nodule that is suspected of being cancerous. Study details All participants who choose to enrol in this study will undergo an initial nodule localisation procedure which involves having their with a localisation wire placed through the lung nodule (under local anaesthesia) during a CT scan. Once the wire has been inserted, participants will then be moved to an operating room where a thoracic surgeon will use the Prana System to take a piece of tissue from the area around the lung nodule. All participants will then be managed as per standard of care for thoracic (chest) surgery and will be asked to stay in hospital for at least 24 hours after the procedure. All participants will then be followed up during their hospital stay and at 14 and 30 days after completion of the procedure. It is hoped this research will determine whether use of the novel Prana system is safe and feasible for use in patients with a lung nodule that requires biopsy to assess if it is cancerous. If the Prana System is found to be safe and effective for biopsy of suspected cancer nodules, there may be scope for further use in the future.

This research program is studying whether giving ketone nutritional supplements to traumatic brain injury (TBI) patients can improve outcomes. To begin this line of research, this project will identify the optimal supplement dose for patients in the intensive care unit and examine the feasibility of using these supplements in TBI patients. Previous studies have used single doses of the supplement in relatively healthy patients. This study will be the first to look at the effect of giving multiple doses of the ketone supplement to critically ill intensive care unit patients. Information obtained from this study is foundational for planned future trials examining the use of ketone supplements in critically ill patients.

This research program is studying whether giving ketone nutritional supplements to traumatic brain injury (TBI) patients can improve outcomes. To begin this line of research, this project will identify the optimal supplement dose for patients in the intensive care unit. In this open-label phase 1 study, 12 patients at Royal Perth Hospital will be given one of 4 dosing regimens of the study intervention (R-1,3-butanediol) over 4 days. This study will be the first to look at the effect of giving multiple doses of the ketone supplement to critically ill intensive care unit patients. Information obtained from this study is foundational for planned future trials examining the use of ketone supplements in critically ill patients.

The treatment of melioidosis is complex; to cure the disease and prevent it from returning, prolonged intravenous antibiotics are given followed by an even longer course of oral antibiotics. The oral antibiotics used for the treatment of melioidosis are prone to causing side effects; over one half of patients will have a side effect and in over 40% this will result in reducing the dose or stopping the antibiotic. This study will investigate if a lower dose of oral antibiotics, given for the same time, will still cure and prevent recurrence of the infection but also cause less side effects than the currently used higher dose.